Publications by authors named "Yohei Ueki"
Objectives: To evaluate the preoperative risk factors for early intravesical recurrence after radical nephroureterectomy (RNU) in patients with upper urinary tract carcinoma (UTUC) according to the history of non-muscle invasive bladder cancer (NMIBC).
Methods: We retrospectively evaluated patients who underwent RNU for UTUC between 2012 and 2022 at 14 hospitals. Early recurrence was defined as intravesical pathologically confirmed recurrence within 1 year after RNU.
Article Synopsis
- A study compared the effectiveness of pembrolizumab and avelumab, two immune checkpoint inhibitors, in treating patients with advanced urothelial carcinoma who had previously undergone chemotherapy.
- Researchers examined patient records from January 2018 to February 2023, focusing on progression-free survival, overall survival, and immune-related adverse events.
- Results indicated no significant differences in survival outcomes between the two treatments, but pembrolizumab showed a potential risk for higher endocrine-related adverse effects compared to avelumab.
We report a case of a patient who developed several urological comorbidities associated with HIV infection. A 53-year-old male was diagnosed with HIV infection and AIDS. After 13 years, microhematuria was found and computed tomography (CT) revealed urolithiasis and a left renal tumor suspected of being renal cell carcinoma.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors are commonly used for treating lung adenocarcinoma but can cause immune-related adverse events, including rare cases of cystitis.
- A 78-year-old woman experienced symptoms of frequent and painful urination while being treated with pembrolizumab, leading to a diagnosis of immune-related cystitis after thorough analysis.
- This case highlights the importance of recognizing and treating such rare side effects and is notable for presenting immunohistochemical analysis of the bladder lining in relation to this condition.
A 70-year-old female with metastatic clear cell renal cell carcinoma was treated with nivolumab. After three dosages, she developed interstitial lung disease which required steroid therapy and nivolumab was discontinued. Thereafter, the target lesion continued to shrinkand the best response was partial response 15 weeks after discontinuation of nivolumab, the reduction rate of which eventually reached 49.
View Article and Find Full Text PDF